House · HR 6130 · 119th Congress
ASAP Act
Summary
This bill adds blood-based dementia screening tests to Medicare coverage starting in 2028. These tests look for early signs of Alzheimer's disease before symptoms appear. Medicare patients would pay nothing out of pocket for an approved test, and Medicare would cover the cost.
In Favor
Catching Alzheimer's early gives patients more time to plan and access treatment. Blood tests are simple and less costly than brain scans or spinal taps. Covering these tests through Medicare means seniors do not have to pay out of pocket for early detection.
Against
Medicare paying for these tests adds new costs to a program already under budget pressure. The bill covers a broad range of test types, which could lead to high spending on tests with unproven benefits. Taxpayers and Medicare funds would bear that cost without a clear spending limit.
Additional Considerations
Purpose & Problem
Is the problem real and worth federal action?
This bill would add blood-based dementia screening tests to Medicare coverage starting in 2028. It targets early or pre-symptom detection of Alzheimer's disease and related dementias in Medicare patients.
Scope & Related Provisions
Does it stay focused, or carry unrelated add-ons?
The bill stays focused on its core purpose of covering early dementia screening tests under Medicare. No unrelated additions appear in the text.
Who Is Affected
Who benefits, and who bears the cost?
Medicare patients could access covered blood-based dementia screening tests at no extra charge beyond standard cost-sharing. Doctors, labs, and the Medicare program would take on new duties related to billing and coverage.
Cost & Funding
Is it affordable and responsibly funded?
The bill adds a new covered service to Medicare, meaning the federal government would pay for qualifying tests under Part B. No specific dollar amount or cost estimate is provided in the source documents.
Risks & Implementation
What could go wrong in practice?
The bill requires FDA clearance or approval for any covered test, so coverage depends on which tests receive that approval by 2028. The Secretary of Health must also decide which additional test types qualify, which could delay full coverage.
For the actual bill text, see congress.gov.
AI-generated · Published 10/14/2026